Dimemorfan phosphate

Cat. No.: HY-B2215
CAS No.: 36304-84-4
Molecular Formula: C₁₈H₂₈NO₄P
Molecular Weight: 353.39
Target: Sigma Receptor
Pathway: Neuronal Signaling
Storage: 4°C, sealed storage, away from moisture
* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

**SOLVENT & SOLUBILITY**

<table>
<thead>
<tr>
<th>Solvent</th>
<th>In Vitro</th>
</tr>
</thead>
<tbody>
<tr>
<td>H₂O</td>
<td>10 mg/mL (28.30 mM; ultrasonic and warming and heat to 60°C)</td>
</tr>
<tr>
<td>DMSO</td>
<td>1 mg/mL (2.83 mM; Need ultrasonic)</td>
</tr>
</tbody>
</table>

**Preparing Stock Solutions**

<table>
<thead>
<tr>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.8297 mL</td>
<td>14.1487 mL</td>
<td>28.2973 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.5659 mL</td>
<td>2.8297 mL</td>
<td>5.6595 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2830 mL</td>
<td>1.4149 mL</td>
<td>2.8297 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 16.67 mg/mL (47.17 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

**BIOLOGICAL ACTIVITY**

Description
Dimemorfan phosphate is a sigma 1 receptor agonist, used as a potent antitussive.

In Vitro
Dimemorfan (5-20 μM) inhibits both fMLP- and PMA-induced ROS production in a concentration-dependent manner and is relatively more potent in inhibiting fMLP-induced ROS production with an IC₅₀ value of 7.0 μM. Dimemorfan (10-50 μM) does not display significant activity in scavenging free radicals by xanthine/xanthine oxidase system. Dimemorfan significantly suppressed Mac-1 upregulation both in PMA- and fMLP-activated groups. Dimemorfan (10-20 μM) significantly suppressed LPS-induced ROS and NO production, and suppresses LPS-induced iNOS protein expression, and both the percentage of the positively stained population and the MCF intensities of MCP-1 and TNF-α in BV2 cytosol. Dimemorfan (20 μM) significantly blocks the degradation of cytosolic Ik-Bα and nuclear translocation of NF-kB p65, as well as the transcriptional activity of NF-kB. [2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo
Dimemorfan (6.25 or 12.5 mg/kg, s.c.) significantly attenuates the BAY k-8644-induced convulsive behaviors, in a dose-
related manner (6.25 mg/kg dimemorfan+BAY k-8644 or 12.5 mg/kg dimemorfan+BAY k-8644 versus Saline+BAY k-8644, P<0.05 and P<0.01, respectively). Dimemorfan significantly attenuates BAY k-8644-induced increases in the c-fos and c-jun protein expression in a dose-dependent manner. Dimemorfan does not significantly affect locomotor activity or produce significant circling behavior in any locomotor pattern in mice[1]. Dimemorfan (1 and 5 mg/kg, i.p.) suppresses the increase of the plasma levels of TNF-α in mice. The infiltration of neutrophils into lung and liver as well as the production of oxidative stress (EB staining) in these tissues induced by LPS is markedly inhibited by the treatment with dimemorfan[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**PROTOCOL**

Animal Administration[1]

C57BL/6 mice receive each morphinan (dextromethorphan, dextrorphan or dimemorfan) compound (20 or 40 mg/kg, i.p. per day) or PCP (2.5 or 5 mg/kg, i.p. per day) once a day for 7 days. Ten minutes after the last treatment with each drug, locomotor activity is measured for 30 min using an automated video-tracking system. Eight test boxes (40 cm×40 cm×30 cm high) are operated simultaneously by an IBM computer. Animals are studied individually during locomotion in each test box, where they are adapted for 10 min before starting the experiment. A printout for each session showed the pattern of the ambulatory movements of the test box. The distance traveled in cm by the animals in horizontal locomotor activity is analyzed. Data are collected and analyzed between 09:00 and 17:00 h.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**CUSTOMER VALIDATION**

- EMBO Mol Med. 2022 May 25;e15373.

See more customer validations on www.MedChemExpress.com

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898                        Fax: 609-228-5909                        E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA